2024-06-300001648257--12-312024Q2false00016482572024-01-012024-06-300001648257us-gaap:CommonStockMember2024-01-012024-06-300001648257us-gaap:CommonStockMember2023-01-012023-06-300001648257us-gaap:RetainedEarningsMember2024-06-300001648257us-gaap:ParentMember2024-06-300001648257us-gaap:NoncontrollingInterestMember2024-06-300001648257us-gaap:AdditionalPaidInCapitalMember2024-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001648257us-gaap:RetainedEarningsMember2023-12-310001648257us-gaap:ParentMember2023-12-310001648257us-gaap:NoncontrollingInterestMember2023-12-310001648257us-gaap:AdditionalPaidInCapitalMember2023-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001648257us-gaap:RetainedEarningsMember2023-06-300001648257us-gaap:ParentMember2023-06-300001648257us-gaap:NoncontrollingInterestMember2023-06-300001648257us-gaap:AdditionalPaidInCapitalMember2023-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001648257us-gaap:RetainedEarningsMember2022-12-310001648257us-gaap:ParentMember2022-12-310001648257us-gaap:NoncontrollingInterestMember2022-12-310001648257us-gaap:AdditionalPaidInCapitalMember2022-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001648257hcm:HCMLShareOptionSchemeMember2022-01-012022-12-310001648257hcm:HCMLShareOptionSchemeMember2022-12-310001648257hcm:HCMLShareOptionSchemeMember2023-01-012023-12-310001648257hcm:HCMLShareOptionSchemeMember2023-12-310001648257srt:MaximumMemberhcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257hcm:LongTermIncentivePlanMember2022-12-310001648257hcm:ExecutiveDirectorMemberhcm:HCMLShareOptionSchemeMember2024-03-012024-03-310001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257us-gaap:OtherNoncurrentLiabilitiesMember2024-06-300001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2024-06-300001648257us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2023-12-310001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-01-012024-06-300001648257us-gaap:RelatedPartyMemberhcm:OtherVenturesSegmentMember2024-01-012024-06-300001648257us-gaap:RelatedPartyMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257us-gaap:NonrelatedPartyMemberhcm:OtherVenturesSegmentMember2024-01-012024-06-300001648257us-gaap:NonrelatedPartyMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:ServicesCollaborationResearchAndDevelopmentFromUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-300001648257hcm:RevenueFromRoyaltiesOfMarketedProductsMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-300001648257hcm:ResearchAndDevelopmentServicesMemberus-gaap:RelatedPartyMember2024-01-012024-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:RelatedPartyMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:EquityMethodInvesteeMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMembersrt:AffiliatedEntityMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2024-01-012024-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:ManufacturingSupplyInvoicedMarketedProductsSalesMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-300001648257hcm:ManufacturingSupplyAllocatedFromUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-300001648257hcm:LicenseAndCollaborationsManufacturingSupplyMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2024-01-012024-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257us-gaap:RelatedPartyMember2024-01-012024-06-300001648257us-gaap:NonrelatedPartyMember2024-01-012024-06-300001648257hcm:ResearchAndDevelopmentServicesMember2024-01-012024-06-300001648257hcm:OtherVenturesSegmentMember2024-01-012024-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2024-01-012024-06-300001648257hcm:MarketedProductsMember2024-01-012024-06-300001648257hcm:LicenseAndCollaborationsManufacturingSupplyMember2024-01-012024-06-300001648257hcm:GoodsDistributionMember2024-01-012024-06-300001648257hcm:CustomerMember2024-01-012024-06-300001648257hcm:CustomerBMember2024-01-012024-06-300001648257hcm:CommercializationServicesMember2024-01-012024-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2024-01-012024-06-300001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:RelatedPartyMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257us-gaap:RelatedPartyMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257us-gaap:NonrelatedPartyMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257us-gaap:NonrelatedPartyMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:ServicesCollaborationResearchAndDevelopmentFromUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMembersrt:AffiliatedEntityMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:OtherCollaborationLicensingRevenueMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:OtherCollaborationLicensingRevenueMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:LicensingFromUpfrontPaymentMemberhcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:GoodsDistributionMemberhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257us-gaap:RelatedPartyMember2023-01-012023-06-300001648257us-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:ResearchAndDevelopmentServicesMember2023-01-012023-06-300001648257hcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2023-01-012023-06-300001648257hcm:OtherCollaborationLicensingRevenueMember2023-01-012023-06-300001648257hcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:MarketedProductsMember2023-01-012023-06-300001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012023-06-300001648257hcm:GoodsDistributionMember2023-01-012023-06-300001648257hcm:CustomerMember2023-01-012023-06-300001648257hcm:CommercializationServicesMember2023-01-012023-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2023-01-012023-06-300001648257hcm:CollaborativeArrangementsMember2024-01-012024-06-300001648257hcm:CollaborativeArrangementsMember2023-01-012023-06-300001648257us-gaap:EquityMethodInvesteeMember2024-01-012024-06-300001648257us-gaap:EquityMethodInvesteeMember2023-01-012023-06-300001648257us-gaap:RetainedEarningsMember2024-01-012024-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionManagementServiceMembersrt:AffiliatedEntityMember2024-01-012024-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMembersrt:AffiliatedEntityMember2023-01-012023-06-300001648257hcm:RelatedPartyTransactionManagementServiceMembersrt:AffiliatedEntityMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-01-012024-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:CapitalAdditionsMember2024-01-012024-06-300001648257us-gaap:CapitalAdditionsMember2024-01-012024-06-300001648257hcm:ShortTermWorkingCapitalLoanFacilityMember2023-11-300001648257hcm:FixedAssetLoanFacilityMember2021-10-310001648257hcm:ShortTermWorkingCapitalLoanFacilityMember2024-06-300001648257hcm:FixedAssetLoanFacilityMember2024-06-300001648257hcm:ShortTermWorkingCapitalLoanFacilityMember2023-12-310001648257hcm:FixedAssetLoanFacilityMember2023-12-310001648257hcm:FixedAssetLoanFacilityMember2024-01-012024-06-300001648257hcm:FixedAssetLoanFacilityMember2023-01-012023-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-01-012023-06-300001648257hcm:HCMLShareOptionSchemeMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2024-01-012024-06-300001648257hcm:CorporateAndReconcilingItemsMember2024-01-012024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2023-01-012023-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2023-01-012023-06-300001648257hcm:CorporateAndReconcilingItemsMember2023-01-012023-06-300001648257hcm:LongTermIncentivePlanMember2024-06-300001648257hcm:LongTermIncentivePlanMember2023-12-310001648257hcm:FixedAssetLoanFacilityMember2021-10-012021-10-310001648257hcm:ShortTermWorkingCapitalLoanFacilityMemberhcm:OneYearChinaLoanPrimeRateMember2023-11-012023-11-300001648257hcm:FixedAssetLoanFacilityMemberhcm:FiveYearChinaLoanPrimeRateMember2021-10-012021-10-310001648257hcm:UnitedStatesAndOthersMember2024-01-012024-06-300001648257country:HK2024-01-012024-06-300001648257country:CN2024-01-012024-06-300001648257hcm:UnitedStatesAndOthersMember2023-01-012023-06-300001648257country:HK2023-01-012023-06-300001648257country:CN2023-01-012023-06-300001648257us-gaap:ProductMemberus-gaap:RelatedPartyMember2024-01-012024-06-300001648257us-gaap:ProductMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300001648257hcm:CommercializationServicesMemberus-gaap:NonrelatedPartyMember2024-01-012024-06-300001648257us-gaap:ProductMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001648257us-gaap:ProductMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:CommercializationServicesMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001648257hcm:OtherVenturesSegmentMember2024-06-300001648257hcm:OncologyOrImmunologySegmentMember2024-06-300001648257hcm:OtherVenturesSegmentMember2023-12-310001648257hcm:OncologyOrImmunologySegmentMember2023-12-3100016482572024-01-010001648257us-gaap:CommonStockMember2024-06-300001648257us-gaap:CommonStockMember2023-12-310001648257us-gaap:CommonStockMember2023-06-300001648257us-gaap:CommonStockMember2022-12-310001648257srt:OtherCurrencyMember2024-06-300001648257currency:USD2024-06-300001648257currency:HKD2024-06-300001648257currency:GBP2024-06-300001648257currency:CNY2024-06-300001648257srt:OtherCurrencyMember2023-12-310001648257currency:USD2023-12-310001648257currency:HKD2023-12-310001648257currency:GBP2023-12-310001648257currency:CNY2023-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2024-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2024-06-300001648257hcm:CorporateAndReconcilingItemsMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2023-12-310001648257hcm:CorporateAndReconcilingItemsMember2023-12-3100016482572023-06-3000016482572022-12-310001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257hcm:HCMLShareOptionSchemeMember2023-01-012023-06-300001648257us-gaap:NoncontrollingInterestMember2024-01-012024-06-300001648257us-gaap:NoncontrollingInterestMember2023-01-012023-06-300001648257hcm:NotLaterThanThreeMonthsMemberus-gaap:NonrelatedPartyMember2024-06-300001648257hcm:LaterThanOneYearMemberus-gaap:NonrelatedPartyMember2024-06-300001648257hcm:BetweenThreeMonthsToSixMonthsMemberus-gaap:NonrelatedPartyMember2024-06-300001648257hcm:BetweenSixMonthsToOneYearMemberus-gaap:NonrelatedPartyMember2024-06-300001648257us-gaap:NonrelatedPartyMember2024-06-300001648257hcm:NotLaterThanThreeMonthsMemberus-gaap:NonrelatedPartyMember2023-12-310001648257hcm:LaterThanOneYearMemberus-gaap:NonrelatedPartyMember2023-12-310001648257hcm:BetweenThreeMonthsToSixMonthsMemberus-gaap:NonrelatedPartyMember2023-12-310001648257hcm:BetweenSixMonthsToOneYearMemberus-gaap:NonrelatedPartyMember2023-12-310001648257us-gaap:NonrelatedPartyMember2023-12-310001648257hcm:NotLaterThanThreeMonthsMember2024-06-300001648257hcm:LaterThanOneYearMember2024-06-300001648257hcm:BetweenThreeMonthsToSixMonthsMember2024-06-300001648257hcm:BetweenSixMonthsToOneYearMember2024-06-300001648257hcm:NotLaterThanThreeMonthsMember2023-12-310001648257hcm:LaterThanOneYearMember2023-12-310001648257hcm:BetweenThreeMonthsToSixMonthsMember2023-12-310001648257hcm:BetweenSixMonthsToOneYearMember2023-12-310001648257us-gaap:ParentMember2024-01-012024-06-300001648257us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001648257us-gaap:RetainedEarningsMember2023-01-012023-06-300001648257srt:MinimumMember2024-01-012024-06-300001648257srt:MaximumMember2024-01-012024-06-300001648257srt:MinimumMember2023-01-012023-12-310001648257srt:MaximumMember2023-01-012023-12-310001648257hcm:VestingBasedOnNonPerformanceMemberhcm:LongTermIncentivePlanMember2024-03-132024-03-130001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2024-06-300001648257hcm:HCMLShareOptionSchemeMember2024-01-012024-06-300001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2023-06-052023-06-050001648257hcm:VestingBasedOnNonPerformanceMemberhcm:LongTermIncentivePlanMember2024-03-130001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2023-06-050001648257hcm:LongTermIncentivePlanMember2023-01-012023-12-310001648257hcm:LongTermIncentivePlanMember2023-01-012023-06-300001648257hcm:LongTermIncentivePlanMember2024-01-012024-06-300001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2024-01-012024-06-3000016482572023-01-012023-12-310001648257srt:AffiliatedEntityMember2024-01-012024-06-300001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-232023-01-230001648257hcm:InmageneBiopharmaceuticalsMemberus-gaap:SubsequentEventMember2024-07-022024-07-020001648257hcm:OncologyOrImmunologySegmentMember2024-01-012024-06-3000016482572022-06-2700016482572021-10-212021-10-210001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-230001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-11-012023-11-300001648257hcm:LicenseAndCollaborationAgreementTakedaPharmaceuticalMember2023-01-012024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2024-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2023-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2023-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2024-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2024-01-012024-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-01-012023-06-300001648257hcm:DueFromRelatedPartiesMemberus-gaap:EquityMethodInvesteeMember2024-06-300001648257hcm:DueFromRelatedPartiesMemberus-gaap:EquityMethodInvesteeMember2023-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2023-01-012023-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2023-01-012023-06-300001648257us-gaap:ParentMember2023-01-012023-06-300001648257us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2024-01-012024-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2024-01-012024-06-3000016482572023-01-012023-06-300001648257us-gaap:RelatedPartyMember2024-06-300001648257us-gaap:EquityMethodInvesteeMember2024-06-300001648257srt:AffiliatedEntityMember2024-06-300001648257hcm:SeroquelMember2024-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2024-06-3000016482572024-06-300001648257us-gaap:RelatedPartyMember2023-12-310001648257us-gaap:EquityMethodInvesteeMember2023-12-310001648257srt:AffiliatedEntityMember2023-12-310001648257hcm:NonControllingShareholdersOfSubsidiariesMember2023-12-3100016482572023-12-31iso4217:USDxbrli:pureiso4217:CNYhcm:areaxbrli:sharesiso4217:USDxbrli:shareshcm:claim

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2024

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ Form 40-F ☐

​

​

​

​

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

​

Exhibit No.

    

Description

Exhibit 99.1

​

Announcement relating to unaudited financial results as of and for the six months ended June 30, 2024

Exhibit 99.2

​

HUTCHMED (China) Limited supplemental disclosures

​

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ JOHNNY CHENG

​

​

Name:

Johnny Cheng

​

​

Title:

Chief Financial Officer

​

Date: July 31, 2024

​

​